secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-004387
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon outlines 2024 clinical milestones: Phase 3 GBS data H1 2024, GA trial start mid-2024
--------------------------------------------------------------------------------

- Phase 3 pivotal data for ANX005 in Guillain-Barré syndrome on track for first half of 2024; potential first approved treatment in U.S.
- Global pivotal program for ANX007 in geographic atrophy (ARCHER II) to initiate mid-2024 with vision preservation as primary endpoint
- Proof-of-concept study for oral C1s inhibitor ANX1502 in cold agglutinin disease to start first half of 2024
- Completed $125 million financing extends operating runway into second quarter 2026
- ANX007 received PRIME designation in EU; to launch head-to-head ARROW trial vs. SYFOVRE in late 2024

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524004387/0001193125-24-004387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524004387/d609684d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-004387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer